文献速递脑血管病认知障碍与痴呆

血浆中临床相关脑内皮细胞生物标志物的鉴定

Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in Plasma.
PubMed 文献 · Stroke · 2023-10-10

研究利用BLSA队列(n=886,2009-2020)从7268种血浆蛋白中鉴定出28种脑内皮细胞富集蛋白,其中4种与白质病变体积显著相关,构建的复合评分可解释11%的白质病变体积变异,并在ARIC研究中验证了其与脑微出血及25年痴呆风险的关联。

要点

  • 从BLSA队列鉴定出28种脑内皮细胞富集血浆蛋白,其中CDH5、CD93、ICAM2、GP1BB与白质病变体积显著相关。
  • 基于3种脑内皮细胞蛋白的复合评分可解释BLSA参与者11%的白质病变体积变异。
  • 在ARIC研究中验证了复合评分、CDH5和RSPO3与白质病变体积的关联,且复合评分和RSPO3与≥1个脑微出血相关。

核心结论

  • 研究鉴定出血浆中与脑小血管病和痴呆风险相关的脑内皮细胞蛋白,并开发了可能用于评估血脑屏障完整性和不良神经血管结局风险的血浆脑内皮细胞蛋白复合评分。

研究设计与样本

  • 研究使用BLSA队列(n=886;2009-2020)数据,通过自动注释算法从7268种血浆蛋白(SomaScanv4.1测量)中鉴定脑内皮细胞富集蛋白,并在ARIC研究(美国多中心;1990-2017)中验证候选标志物与白质病变体积、脑微出血和腔隙性梗死的关联,以及其与25年随访期间痴呆风险的关系。

主要发现

  • 在28种脑内皮细胞富集蛋白中,4种与白质病变体积显著相关(CDH5、CD93、ICAM2、GP1BB),另一种接近显著(RSPO3)。
  • 基于3种脑内皮细胞蛋白的复合评分可解释BLSA参与者白质病变体积变异的11%。
  • 在ARIC研究中重复了复合评分、CDH5和RSPO3与白质病变体积的关联,并进一步显示复合评分和RSPO3与≥1个脑微出血的存在相关。
  • 复合评分、CDH5和RSPO3与25年痴呆风险相关。

临床怎么用

  • 原文未据此给出推荐;作者认为血浆脑内皮细胞蛋白复合评分可能用于评估血脑屏障完整性和不良神经血管结局风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proteins expressed by brain endothelial cells (BECs), the primary cell type of the blood-brain barrier, may serve as sensitive plasma biomarkers for neurological and neurovascular conditions, including cerebral small vessel disease. METHODS: Using data from the BLSA (Baltimore Longitudinal Study of Aging; n=886; 2009-2020), BEC-enriched proteins were identified among 7268 plasma proteins (measured with SomaScanv4.1) using an automated annotation algorithm that filtered endothelial cell transcripts followed by cross-referencing with BEC-specific transcripts reported in single-cell RNA-sequencing studies. To identify BEC-enriched proteins in plasma most relevant to the maintenance of neurological and neurovascular health, we selected proteins significantly associated with 3T magnetic resonance imaging-defined white matter lesion volumes. We then examined how these candidate BEC biomarkers related to white matter lesion volumes, cerebral microhemorrhages, and lacunar infarcts in the ARIC study (Atherosclerosis Risk in Communities; US multisite; 1990-2017). Finally, we determined whether these candidate BEC biomarkers, when measured during midlife, were related to dementia risk over a 25-year follow-up period. RESULTS: Of the 28 proteins identified as BEC-enriched, 4 were significantly associated with white matter lesion volumes (CDH5 [cadherin 5], CD93 [cluster of differentiation 93], ICAM2 [intracellular adhesion molecule 2], GP1BB [glycoprotein 1b platelet subunit beta]), while another approached significance (RSPO3 [R-Spondin 3]). A composite score based on 3 of these BEC proteins accounted for 11% of variation in white matter lesion volumes in BLSA participants. We replicated the associations between the BEC composite score, CDH5, and RSPO3 with white matter lesion volumes in ARIC, and further demonstrated that the BEC composite score and RSPO3 were associated with the presence of ≥1 cerebral microhemorrhages. We also showed that the BEC composite score, CDH5, and RSPO3 were associated with 25-year dementia risk. CONCLUSIONS: In addition to identifying BEC proteins in plasma that relate to cerebral small vessel disease and dementia risk, we developed a composite score of plasma BEC proteins that may be used to estimate blood-brain barrier integrity and risk for adverse neurovascular outcomes.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Cordon J, Duggan MR, Gomez GT, et al. Identification of Clinically Relevant Brain Endothelial Cell Biomarkers in Plasma. Stroke. 2023. PMID: 37814955. doi:10.1161/STROKEAHA.123.043908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。